

(use as many sheets as necessary)

INFORMATION DIS
 STATEMENT BY
 AUG 29 2005
 PATENT & TRADEMARK OFFICE
 use of many sheets as r

Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker

Sheet	1	of	4	Attorney Docket Number	21288YP
-------	---	----	---	------------------------	---------

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	8	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003
	9	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003
	10	PCT	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003
	11	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003
	12	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002
	13	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004
	14	PCT	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004
	15	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004
	16	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004
	17	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004

/Michael Barker/

07/10/2007

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

AUG 29 2005
(use as many sheets as necessary)

(use as many sheets as necessary)

Sheet

25

of

4

Application Number

10/537,476

Filing Date

June 3, 2005

First Named Inventor

Joseph L. Duffy, et al.

Group Art Unit

1626

Examiner Name

M. Barker

Attorney Docket Number

21288YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	18	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
	19	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
	20	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
	21	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001
	22	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
	23	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
	24	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
	25	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
	26	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
	27	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

**Examiner
Signature**

/Michael Barker/

Date Considered

07/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Use as many sheets as necessary)

181
AUG 29 2005
PATENT & TRADEMARK OFFICE
Use as many sheets as necessary

Sheet

3

of

4

Application Number

10/537,476

Filing Date

June 3, 2005

First Named Inventor

Joseph L. Duffy, et al.

Group Art Unit

1626

Examiner Name

M. Barker

Attorney Docket Number

21288YP

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	28	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002
	29	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
	30	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
	31	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004
	32	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
	33	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
	35	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005
	37	PCT	WO 2005/002530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003

**Examiner
Signature**

/Michael Barker/

Date Considered

07/10/2007


*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



COMPLETE IF KNOWN

Application Number	10/537,476
Filing Date	June 3, 2005
First Named Inventor	Joseph L. Duffy, et al.
Group Art Unit	1626
Examiner Name	M. Barker
Attorney Docket Number	21288YP

Sheet

1

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	38	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.
	39	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.
	40	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.
	41	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.
	42	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol. 12, 2004, pages 87-100.
	43	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.
	44	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4128-4134.
	45	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, 2004, pages 4135-4141.
	46	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.
	47	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.

Examiner
Signature

/Michael Barker/

Date
Considered

07/10/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005